Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene

Goulding, J. M. R.; Price, Charlotte L; Defty, Charlotte; Hulangamuwa, C. S.; Bader, Erwin; Ahmed, Imran

doi:10.1111/j.1365-2133.2010.10077.x

Cited by 60 publications

(56 citation statements)

References 31 publications

(101 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, the prevalence of ED in both psoriasis patients and healthy subjects is in line with previous reports, indicating high levels of ED in psoriasis patients (Chung et al, 2012;Goulding et al, 2011;Martin-Morales et al, 2001;Sierra et al, 2012). Accordingly, the population of patients with moderate to severe psoriasis may be considered a high-risk population for ED.…”

Section: Discussionsupporting

confidence: 92%

“…Inourstudy,weobserved that smoking is involved in a greater risk of ED and is more prevalent among moderate to severe psoriasis patients. Other studies have found a significant association between arterial hypertension, dyslipidemia or diabetes mellitus and ED in patients with psoriasis (Table 1) (Cabete et al, 2014;Chen et al, 2013;Chung et al, 2012;Goulding et al, 2011). These factors, such as smoking, anxiety, and depression, are more prevalent among psoriasis patients than in the general population and are also associated with a higher risk of ED (Corona, Mannucci, Forti, & Maggi, 2009;Martin-Morales et al, 2001;Nunes, Labazi, & Webb, 2012).…”

Section: Discussionmentioning

confidence: 92%

“…The prevalence among Spanish men is similar for this age range, from 22.7 to 57.4 % (Sierra, Vallejo-Medina, Santos-Iglesias, & LameirasFernandez, 2012).Inmenwithpsoriasis,the prevalence of ED appears to be greater than in the general population, from 58 to 81 % (Cabete, Torres, Vilarinho, & Ferreira, 2014;Goulding et al, 2011;Tasliyurt et al, 2014). This higher rate of ED in psoriasis patients may be due to different factors such as unhealthy lifestyles (high prevalence of smoking and obesity), organic factors (chronic inflammation and premature atherosclerosis), and high psychosocial impairment (high prevalence of anxiety and depression).…”

Section: Introductionmentioning

confidence: 91%

See 2 more Smart Citations

Prevalence and Associated Factors of Erectile Dysfunction in Patients With Moderate to Severe Psoriasis and Healthy Population: A Comparative Study Considering Physical and Psychological Factors

et al. 2016

View full text Add to dashboard Cite

Recent studies have shown that psoriasis is associated with an increased prevalence of erectile dysfunction. To our knowledge, no comparative study has considered simultaneously the role of organic factors and psychological factors in this process. We performed a prospective case series study matched by age to explore the prevalence of erectile dysfunction in psoriasis patients compared to a healthy population and to investigate the role of anxiety, depression, and cardiovascular risk factors in the relationship between psoriasis and erectile dysfunction. The healthy group was matched by frequency to cases by age. Seventy-nine patients with moderate to severe psoriasis and 79 healthy controls participated in the study. Participants completed the Massachusetts General Hospital Sexual Functioning Questionnaire and the Hospital Anxiety and Depression Scale. Psoriasis patients had an increased prevalence of erectile dysfunction in comparison to controls, 34.2 vs. 17.7 % (p < .05). Multivariate analysis showed a significant association between erectile dysfunction and age, smoking and anxiety/depression, but not with psoriasis per se. In conclusion, the higher prevalence of smoking and anxiety/depression among patients with moderate to severe psoriasis probably explains the higher prevalence of erectile dysfunction in this population.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

Prevalence and Associated Factors of Erectile Dysfunction in Patients With Moderate to Severe Psoriasis and Healthy Population: A Comparative Study Considering Physical and Psychological Factors

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The impact of depression on sexual dysfunction in psoriatic patients is controversial (non-related/positive correlation). MTX and retinoids have been were also found to be related with loss of libido and erectile dysfunction 69,70 .…”

Section: Erectile Dysfunctionmentioning

confidence: 99%

Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management

Kalkan¹

2017

TURKDERM

View full text Add to dashboard Cite

©Copyright 2017 by Turkish Society of Dermatology and Venereology Turkderm-Turkish Archives of Dermatology and Venereology published by Galenos Yayınevi. Öz IntroductionPsoriasis, with a worldwide prevalence of 2-3%, is now assumed as a systemic chronic inflammatory disease accompanied by comorbidities while it was accepted as a disease limited only to the skin in the past 1 . Psoriasis and its comorbidities were the main focused topic at several sessions of the 73 rd Annual Meeting of the American Academy of Dermatology and, especially, systemic disease concept was emphasized 2 . Therefore, recent publications suggest that the term psoriatic disease would be a better nomination instead of psoriasis 3 . In this review, learning screening recommendations developed for early detection and treatment of comorbidities as well as integrated, multidisciplinary approach for disease management have been targeted by reviewing psoriasis and accompanying comorbidities. Comorbidities are more frequently seen in 15% of psoriasis patients who have moderate to severe psoriasis due to increased inflammatory impact and common pathogenesis. Consistent monitoring and systemic treatment are required to prevent development of comorbidities. There are several Tüm dünyada %2-3 oranında görülme sıklığına sahip psoriazis, geçmişte sadece deriye sınırlı kabul edilirken, günümüzde birçok komorbiditenin eşlik ettiği kronik sistemik enflamatuvar bir hastalık olarak ele alınmaktadır. Orta-şiddetli düzeyde psoriazisi olanlarda daha sık görülen komorbiditelerle ilgili çeşitli sınıflamalar mevcuttur. Basit olarak klasik, kronik sistemik enflamasyonla ilişkili, yaşam tarzı ile ilgili ve tedavi ile ilgili olarak sınıflanabileceği gibi medikal komorbiditeler, psikiyatrik/psikolojik komorbiditeler ve komorbiditelere katkı yapan durumlar şeklinde de sınıflanabilmektedir. Bu derlemede psoriazis ve eşlik eden komorbiditelerin gözden geçirilmesiyle; komorbiditelerin erken tanı ve tedavisini sağlama, komorbiditilerin erken tespitine yönelik geliştirilen tarama önerilerini öğrenme ve hastalığın yönetiminde entegre, multidisipliner yaklaşım ile uzun dönem hastalık kontrolü ve hayat kalitesinde düzelme sağlamak hedeflenmektedir. Anahtar Kelimeler: Psoriazis, komorbidite, sistemik hastalık Psoriasis, with a worldwide prevalence of 2-3%, is now assumed as a systemic chronic inflammatory disease accompanied by comorbidities while it was accepted as a disease limited only to the skin in the past. There are several classifications of the comorbidities which are more common in patients with moderate to severe psoriasis. Simply, comorbidities can be classified as classic, emerging, related to lifestyle, related to treatment. They can also be categorized as medical comorbidities, psychiatric/psychologic comorbidities, and behaviors contributing to medical and psychiatric comorbidities. In this review, providing early diagnosis and treatment of comorbidities, learning screening recommendations for early detection and long-term disease control and improvemen...

show abstract

“…propose that the psychologic burden associated with psoriasis is a stronger component of psoriasis burden than physical aspects of the disease, such as disease severity, location or duration. On a promising note, patient complaints of psoriasis‐related social and sexual difficulties have significantly decreased since the advent of highly efficacious biologic therapeutics for the treatment of psoriasis 16, 17, 18…”

Section: Introductionmentioning

confidence: 99%

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

Blauvelt

Reich

Mehlis

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundPsoriasis can greatly impact patients’ lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin‐17A, has demonstrated good efficacy and safety in the treatment of moderate‐to‐severe psoriasis and psoriatic arthritis with a rapid onset of action and sustained response.ObjectiveThis analysis using the CLEAR study, a phase 3b double‐blind study comparing the efficacy and safety of secukinumab vs. ustekinumab in adults with moderate‐to‐severe plaque psoriasis, evaluated the treatment effects on patient's daily activities and personal relationships.MethodsImpact on daily activities (interference with home/shopping/garden, and influence on clothes worn) and impact on personal relationships (problems with partner/others, and sexual difficulties) as well as their corresponding subscales were selected from the Dermatology Life Quality Index scale and evaluated for patients treated with secukinumab vs. ustekinumab from the CLEAR study. Treatment differences in mean scores and proportions of responders (score = 0, indicating no impact) were evaluated through 52 weeks. Time to response was evaluated through Week 16.ResultsSignificant differences between secukinumab and ustekinumab were observed for daily activities and personal relationships at Week 16 and sustained through Week 52 (Week 52 response rates for daily activities: 82.9% vs. 73.5%, including interference with home/shopping/garden: 88.5% vs. 78.2%, and influence on clothes worn: 85.6% vs. 74.4%; personal relationships: 86.1% vs. 73.7%, including problems with partner/others: 86.6% vs. 74.8%, and sexual difficulties: 88.5% vs. 74.3%; all P < 0.01). The median time to response was 4 weeks for secukinumab vs. 8 weeks for ustekinumab for daily activities and personal relationships (both P < 0.05).ConclusionSecukinumab treatment helps patients with moderate‐to‐severe plaque psoriasis have a more normal life faster when compared to ustekinumab, by providing greater and sustained improvement in clothing choice and sexual functioning.

show abstract

Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene

Cited by 60 publications

References 31 publications

Prevalence and Associated Factors of Erectile Dysfunction in Patients With Moderate to Severe Psoriasis and Healthy Population: A Comparative Study Considering Physical and Psychological Factors

Prevalence and Associated Factors of Erectile Dysfunction in Patients With Moderate to Severe Psoriasis and Healthy Population: A Comparative Study Considering Physical and Psychological Factors

Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

Contact Info

Product

Resources

About